Greenwich LifeSciences, Inc. (GLSI)
NASDAQ · Manufacturing · Pharmaceutical preparations
$18.22+$0.1200 (+0.66%) on the dayAs of the close; data may be delayed.
GLSI price, last 12 months
Key stats
- Previous close
- $18.10
- Open
- $18.00
- Day range
- $18.00 – $18.69
- 52-week range
- $7.78 – $34.10
- Volume
- 67.1K
- Avg volume (20 days)
- 130.5K
- Market cap
- $267.4M
Performance
1W−4.1%
1M−0.1%
3M−8.0%
6M−28.1%
YTD−13.3%
1Y+66.5%
vs S&P 500, 1Y+49.7 pts
Technicals and fundamentals
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $267.4M